Johnson & Johnson announced that the China National Medical Products Administration has approved Teclistamab Injection as a ...

Barclays analyst Balaji Prasad maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $242.00. The ...

An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug ...

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced positive topline results from ...

From the Nutrition Laboratory and the Division of Gastroenterology, Department of Medicine, Mount Sinai Hospital ... 1000 U.S.P. units per milliliter, Organon, Incorporated, West Orange, New ...

Along with the Pfizer collaboration, it is also working with on an app/medicine combination for patients ... Partners and Ampersand Capital Part Organon is paying $175 million upfront to buy ...

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic ... as the most bothersome symptom in atopic dermatitis. Organon is paying $175 million upfront to buy Roivant's ...

On a per-share basis, the Jersey City, New Jersey-based company said it had profit of $1.38. Earnings, adjusted for one-time gains and costs, came to 87 cents per share. The results exceeded Wall ...

Organon & Co. ( (OGN)) has released its Q3 earnings. Here is a breakdown of the information Organon & Co. presented to its investors. Organon & Co. is a global healthcare company focused on ...

Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 ...